SEC Form 4 · accession 0000899243-19-007017
MADRIGAL PHARMACEUTICALS, INC. · MDGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc R Schneebaum
Officer — Chief Financial Officer
Period of report
Mar 7, 2019
Accepted (ET)
Mar 11, 2019 · 3:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157601
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $127.96 | Mar 7, 2019 | A | 28,000 | A | — | Mar 7, 2029 | Common Stock | 28,000 | 28,000 | D |
Explanation of responses
- F1The option vests as to 25% of the shares on the first anniversary of the date of grant (March 7, 2020) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
Remarks
** As attorney-in-fact for Reporting Person